EVE is a deep generative model combining evolutionary and human population data to estimate variant deleteriousness on a proteome-wide scale.

The U.S. is AstraZeneca’s largest market by sales and is also home to 19 R&D, manufacturing, and commercial sites.

Scripps Research uses advanced AI computing to speed HIV vaccine development by rapidly analyzing clinical data.

ToxPredictor accurately predicts drug induced liver injury (DILI) to offer a valuable “go/no-go” tool in clinical decision making.

This latest corporate clash has Alkermes working to beat back a challenge from H. Lundbeck for sleep disorder drug developer Avadel Pharmaceuticals.

Findings represent a detailed resource for future research that could lead to the development of new biomarkers and targeted therapeutics for T1D.

The Virtual Cell Pharmacology Initiative (VCPI) is an open source platform designed to build a standardized framework for virtual cell models.

Novartis’ $23 billion investment in U.S.-based infrastructure over the next five years is designed to increase manufacturing capacity.

Cryo-EM revealed HIV-1 integrase’s distinct structures as it shifts between its two roles of DNA integration and RNA-binding.

The study evaluates the long-term cognitive abilities in the mice with over expression of Sox9 or elimination of the gene.

New live-cell DNA damage sensor lets scientists watch repair unfold in real time, potentially opening doors for cancer and aging research.

In a study in IBD patients, scientists observed shifts in gut chemistry, among other changes, that could lead to new treatment strategies.